VYNE Therapeutics (VYNE) shares were edging higher Monday morning after the biopharmaceutical company reported "positive" phase 1a results for its novel BD2-selective BET inhibitor VYN202.
The company said the results support the inhibitor's potential as a new oral treatment for various immune-mediated disorders.
VYN202 showed a favorable safety and tolerability profile without any drug-related adverse events in the phase 1a trial as well as "robust pharmacodynamic activity," VYNE said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.